Literature DB >> 28711962

The relation between hemoglobin variability and carotid intima-media thickness in chronic hemodialysis patients.

Safa Ersen Ganidagli1, Orcun Altunoren2, Ertuğrul Erken3, Ismet Onder Isık4, Berivan Ganidagli1, Necmi Eren5, Yasemin Coskun Yavuz6, Ozkan Gungor3.   

Abstract

PURPOSE: Hemoglobin variability is a common problem among hemodialysis patients. We have previously demonstrated an association between Hb variability and left ventricular mass index. In this study, we investigated a possible relation between Hb variability and carotid intima-media thickness (CIMT).
METHODS: Twelve-month hemoglobin (Hb) values of 135 patients on maintenance hemodialysis were examined retrospectively. The range of 11-12 gr/dl was accepted as normal according to the KDOQI guidelines. Hemoglobin levels were classified as: Hb < 11 gr/dl:Low, Hb = 11-12 gr/dl:Normal and Hb > 12 gr/dl:High. According to 12-month Hb trajectory, the patients were divided into three groups: low-normal (LN), normal-high (NH) and low-high (LH). The CIMT measurements were taken on common carotid arteries bilaterally, and the average of these measurements were taken. The groups were compared in terms of CIMT measurements, demographic and laboratory features.
RESULTS: The LN, NH and LH groups were similar in terms of age, gender, incidence of diabetes mellitus, hypertension and cardiovascular diseases. Duration of hemodialysis, hemodialysis adequacy, serum lipids and CaxP products were also similar among the groups. The mean CIMT value was 0.601 ± 0.107, 0.744 ± 0.139 and 0.604 ± 0.134 mm in the LN, LH and NH groups, respectively (p < 0.001). CIMT was significantly higher in LH than in the other two groups.
CONCLUSIONS: In our study, when the three groups with similar risk factors for atherosclerosis were examined, we found that the LH group with the highest hemoglobin variability has the highest CIMT. This study is the first study to demonstrate that Hb variability is associated with an increase in CIMT in HD patients.

Entities:  

Keywords:  Anemia; Carotid intima-media thickness; End-stage renal disease; Hemodialysis; Hemoglobin variability

Mesh:

Substances:

Year:  2017        PMID: 28711962     DOI: 10.1007/s11255-017-1651-6

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  41 in total

1.  Impact of carotid atherosclerosis on long-term mortality in chronic hemodialysis patients.

Authors:  Akihiko Kato; Takako Takita; Yukitaka Maruyama; Hiromichi Kumagai; Akira Hishida
Journal:  Kidney Int       Date:  2003-10       Impact factor: 10.612

2.  Carotid artery thickness in children and young adults with end stage renal disease.

Authors:  Hakan M Poyrazoğlu; Ruhan Düşünsel; Ali Yikilmaz; Nazmi Narin; Ruksan Anarat; Zübeyde Gündüz; Abdulhakim Coşkun; Ali Baykan; Ahmet Oztürk
Journal:  Pediatr Nephrol       Date:  2006-08-30       Impact factor: 3.714

Review 3.  Vessel wall alterations in patients with renal failure.

Authors:  K H Rahn; M Barenbrock; M Hausberg; M Kosch; B Suwelack; J Witta
Journal:  Hypertens Res       Date:  2000-01       Impact factor: 3.872

Review 4.  Anaemia in end-stage renal disease: pathophysiological considerations.

Authors:  K U Eckardt
Journal:  Nephrol Dial Transplant       Date:  2001       Impact factor: 5.992

5.  Studies of the vessel wall properties in hemodialysis patients.

Authors:  M Barenbrock; C Spieker; V Laske; S Heidenreich; H Hohage; J Bachmann; A P Hoeks; K H Rahn
Journal:  Kidney Int       Date:  1994-05       Impact factor: 10.612

6.  Cross-sectional association of serum phosphate with carotid intima-medial thickness in hemodialysis patients.

Authors:  Eiji Ishimura; Hiromichi Taniwaki; Tsutomu Tabata; Yoshihiro Tsujimoto; Shuichi Jono; Masanori Emoto; Tetsuo Shoji; Masaaki Inaba; Takashi Inoue; Yoshiki Nishizawa
Journal:  Am J Kidney Dis       Date:  2005-05       Impact factor: 8.860

7.  Selective blockade of endothelium-dependent and glyceryl trinitrate-induced relaxation by hemoglobin and by methylene blue in the rabbit aorta.

Authors:  W Martin; G M Villani; D Jothianandan; R F Furchgott
Journal:  J Pharmacol Exp Ther       Date:  1985-03       Impact factor: 4.030

8.  Carotid intima-media thickness in maintenance hemodialysis patients: role of cardiovascular risk factor.

Authors:  Shahrzad Ossareh; Anoosha Alaei; Daryoush Saedi
Journal:  Iran J Kidney Dis       Date:  2011-07       Impact factor: 0.892

9.  Cardiac and arterial interactions in end-stage renal disease.

Authors:  G M London; A P Guerin; S J Marchais; B Pannier; M E Safar; M Day; F Metivier
Journal:  Kidney Int       Date:  1996-08       Impact factor: 10.612

Review 10.  Arterial structure and function in end-stage renal disease.

Authors:  Alain P Guérin; Bruno Pannier; Sylvain J Marchais; Gérard M London
Journal:  Curr Hypertens Rep       Date:  2008-04       Impact factor: 5.369

View more
  4 in total

Review 1.  Hemodialysis-induced cardiovascular disease.

Authors:  Shadi Ahmadmehrabi; W H Wilson Tang
Journal:  Semin Dial       Date:  2018-04-06       Impact factor: 3.455

2.  Time-averaged hemoglobin values, not hemoglobin cycling, have an impact on outcomes in pediatric dialysis patients.

Authors:  Sevcan A Bakkaloğlu; Yaşar Kandur; Erkin Serdaroğlu; Aytül Noyan; Aysun Karabay Bayazıt; Mehmet Taşdemir; Sare Gülfem Özlü; Gül Özçelik; İsmail Dursun; Caner Alparslan; Meltem Akcaboy; Yeşim Özdemir Atikel; Gönül Parmaksız; Bahriye Atmış; Lale Sever
Journal:  Pediatr Nephrol       Date:  2018-08-13       Impact factor: 3.714

3.  Sitagliptin on Carotid Intima-Media Thickness in Type 2 Diabetes Mellitus Patients and Anemia: A Subgroup Analysis of the PROLOGUE Study.

Authors:  Zhengri Lu; Genshan Ma; Lijuan Chen
Journal:  Mediators Inflamm       Date:  2020-05-11       Impact factor: 4.711

4.  Association between hemoglobin variability and incidence of hypertension over 40 years: a Korean national cohort study.

Authors:  Minkook Son; Junyong Park; Kyungil Park; Sung Yang
Journal:  Sci Rep       Date:  2020-07-21       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.